Facebook
Twitter
LinkedIn
Forward
Cases and Controversy in Glaucoma: Adventures in a Wonderland of Options (CME Monograph)
Activity Description and Purpose
Topical treatments for glaucoma have important limitations related to efficacy over time, adverse effects, and the burden of frequent instillation. When patients and their clinicians decide that it is time to move to a different treatment modality, the vast array of options can be daunting. In this educational activity, based on a live virtual symposium held during the 2020 Annual Meeting of the American Academy of Ophthalmology, experts discuss recent advances in both implantable sustained drug delivery and minimally invasive glaucoma surgery. Several cases will be used to illustrate patient-centered decision-making to achieve the best possible visual and quality of life outcomes. The desired results of this educational activity are for learners to employ patient-centered care to select treatment options for glaucoma that achieve the best possible outcomes.
Target Audience
This educational activity is intended for ophthalmologists caring for patients with glaucoma.
Learning Objectives
Upon completion of this activity, participants will be better able to:
- Discuss safety and efficacy data for approved and emerging sustained drug delivery devices for glaucoma
- Identify patients with glaucoma most likely to benefit from sustained drug delivery
- Select appropriate MIGS procedures according to individual patient needs and characteristics
Disclosure Policy Statement
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Faculty
Ike K. Ahmed, MD, FRCSC, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aequus BioPharma, Inc; Aerie Pharmaceuticals, Inc; Akorn, Inc; Alcon; Allergan; ArcScan, Inc; Bausch & Lomb Incorporated; Beaver-Visitec International; Beyeonics Surgical Ltd; Camras Vision, Inc; Carl Zeiss Meditec, Inc; CorNeat Vision Ltd; Ellex; ELT Sight, Inc; ElutiMed; Equinox; Genentech, Inc; Glaukos Corporation; Injectsense, Inc; IRIDEX Corporation; iSTAR; Ivantis Inc; Johnson & Johnson Vision Care, Inc; Kelotec Inc; LayerBio, Inc; Leica Microsystems; Long Bridge Medical, Inc; MicroOptx; MicroSurgical Technology; Mynosys Cellular Devices Inc; New World Medical, Inc; Ocular Instruments; Ocular Therapeutix, Inc; Omega Ophthalmics; Polyactiva Pty Ltd; Sanoculis Ltd; Santen Inc; ScienceBased Health; Sight Sciences; Smartlens, Inc; Strõma Medical Corporation; Thea Pharmaceuticals Limited; Vialase, Inc; Vizzario; and W. L. Gore & Associates, Inc; Contracted Research: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Camras Vision, Inc; Glaukos Corporation; Ivantis Inc; Johnson & Johnson Vision Care, Inc; New World Medical, Inc; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon; Allergan; Carl Zeiss Meditec, Inc; Johnson & Johnson Vision Care, Inc; MicroSurgical Technology; and Mundipharma International.
Sahar Bedrood, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Glaukos Corporation; and Santen Inc; Contracted Research: Allergan; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; and Glaukos Corporation.
E. Randy Craven, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Ivantis Inc; Sight Sciences; and W. L. Gore & Associates, Inc; Contracted Research: Allergan; Sight Sciences; and W. L. Gore & Associates, Inc.
Deborah Ristvedt, DO, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Sight Sciences; Contracted Research: Allergan; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon; Allergan; Glaukos Corporation; and Sight Sciences.
New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure
Kateki Vinod, MD, has no relevant commercial relationships to disclose.
Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; iSTaR; New World Medical, Inc; and Notal Vision.
Disclosure Attestation
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
Accreditation Statement
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.
AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.
Off-Label Discussion
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
https://www.nyee.edu/education/cme
CME Provider Contact Information
For questions about this activity, call 917-270-7571.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Allergan, EyeNet, or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 233
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Clicking Register indicates that you have reviewed the CME information for this activity.
Learning Method and Medium
This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.